AstraZeneca has announced that its Tezspire (tezepelumab) received approval from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in the EU for self-administration in severe asthma patients aged 12 years and above.

The CHMP granted a positive opinion for the self-administration of Tezspire in a single-use, pre-filled pen.

Being developed in collaboration with Amgen, Tezspire is a first-in-class human monoclonal antibody inhibiting TSLP action.

It has already received approval for the same indication in Japan, the EU, the US and other countries.

The company stated that the regulatory opinion does not require a European Commission (EC) decision due to the nature of the variation in the Type-II label.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “Tezspire is the first and only biologic approved in Europe for patients with severe asthma with no phenotype or biomarker limitation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With the approval of the Tezspire pre-filled pen, we can give patients in Europe greater flexibility and support physicians in treating a broad population of severe asthma patients.”

The regulatory approval was based on the data obtained from the PATHFINDER clinical trial programme that included data from the Phase I PATH-BRIDGE trial and the Phase III PATH-HOME trial.

Throughout the PATH-HOME trial, 92% of the patients, healthcare providers, and caregivers could successfully administer Tezspire in the clinic and at home.

In the PATH-HOME trial, Tezspire showed improved asthma control and a safety profile consistent with previous clinical trials.

The company expects to receive the US Food and Drug Administration (FDA) decision on the new pre-filled pen and self-administration in the first half of this year.

This content was updated on 25 January 2024